Kymera Therapeutics reported an insider sale tied to an established trading plan on April 14, 2026. Chief Business Officer Noah Goodman disposed of 1,347 shares of common stock at $90.0 per share, producing proceeds of $121,230. The sale was carried out under a Rule 10b5-1 trading plan that Goodman adopted on December 10, 2025, and was disclosed in a Form 4 filing with the Securities and Exchange Commission.
After the transaction, Goodman directly holds 50,195.438 shares of Kymera Therapeutics. The sale occurred while the company’s shares were trading at $86.14, a price point that follows an overall 244% increase in the stock over the trailing 12 months. InvestingPro analysis included in reporting indicates that Kymera is trading above what InvestingPro considers its Fair Value.
The corporate backdrop includes a mix of regulatory progress and partnership-driven milestones. The U.S. Food and Drug Administration granted Fast Track designation to KT-621 for the treatment of moderate to severe eosinophilic asthma, a regulatory pathway intended to expedite development and review of therapies for serious conditions. Separately, Gilead Sciences exercised its option to exclusively license Kymera’s KT-200, an oral CDK2 molecular glue degrader, triggering a $45 million milestone payment to Kymera. Under that agreement Gilead will take KT-200 forward into the studies required to support an investigational new drug (IND) filing in 2027.
On the equity research front, H.C. Wainwright reiterated a Buy rating for Kymera and set a price target of $134 after conversations with company management. Stephens raised its price target to $100 while maintaining an Overweight rating; that adjustment followed Kymera’s recent financial results, which the firm characterized as consistent with prior guidance.
Kymera also signaled upcoming scientific disclosure: the company will present data from the KT-621 BroADen Phase 1b clinical trial in atopic dermatitis at the American Academy of Dermatology 2026 Annual Meeting. These events mark several near-term catalysts for the company’s clinical programs and partnership portfolio.
InvestingPro Tips noted that Kymera’s balance sheet shows more cash than debt, but the company remains unprofitable and analysts do not expect it to reach profitability this year. The report references 10 additional ProTips and a comprehensive Pro Research Report for KYMR available through InvestingPro for subscribers seeking deeper analysis.
Summary
Noah Goodman’s planned sale of 1,347 Kymera shares netted $121,230 and left him with 50,195.438 shares. The company is trading at $86.14 after a 244% rise over the past year, but InvestingPro flags KYMR as trading above its Fair Value. Regulatory progress for KT-621, a $45 million milestone from Gilead on KT-200, analyst target upgrades, and an upcoming data presentation at AAD 2026 round out recent corporate developments.